


## ACHe-IN-59

<b>Cat. No.:</b>	HY-157978
<b>CAS No.:</b>	2957916-86-6
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>28</sub> N <sub>2</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	452.5
<b>Target:</b>	Cholinesterase (ChE); Amyloid-β
<b>Pathway:</b>	Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	ACHe-IN-59 (compounds 3b) is an AChE inhibitor, with an IC <sub>50</sub> value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ <sub>1-42</sub> , protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD) <sup>[1]</sup> .										
<b>IC<sub>50</sub> &amp; Target</b>	AChE 0.05 μM (IC <sub>50</sub> )	BChE 4.68 μM (IC <sub>50</sub> )	Aβ 1-42								
<b>In Vitro</b>	<p>ACHe-IN-59 (compounds 3b) (50/100/500/1000 μg/ mL, 5 min) can inhibit the activity of ChEs, with the IC<sub>50</sub> values for AChE and BuChE of 0.05 μM and 4.68 μM, respectively, indicating that AChE-IN-59 is selective for AChE subtype<sup>[1]</sup>.</p> <p>ACHe-IN-59 (50/100/500/1000 μg/ mL, 5 min) shows well antioxidant activity in vitro in tests of Ferric ion reducing antioxidant power (FRAP) and DPPH free radical scavenging capacity<sup>[1]</sup>.</p> <p>ACHe-IN-59 (25 μM, 5 min) has no cytotoxic effect on SH-SY5Y cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>SH-SY5Y</td> </tr> <tr> <td>Concentration:</td> <td>0/6.25/12.5/25/50/100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>5 h</td> </tr> <tr> <td>Result:</td> <td>Showed a good neuroprotective effect in the range of 6.25-25 μM and did not affect SH-SY5Y cell viability below 25 μM.</td> </tr> </table>			Cell Line:	SH-SY5Y	Concentration:	0/6.25/12.5/25/50/100 μM	Incubation Time:	5 h	Result:	Showed a good neuroprotective effect in the range of 6.25-25 μM and did not affect SH-SY5Y cell viability below 25 μM.
Cell Line:	SH-SY5Y										
Concentration:	0/6.25/12.5/25/50/100 μM										
Incubation Time:	5 h										
Result:	Showed a good neuroprotective effect in the range of 6.25-25 μM and did not affect SH-SY5Y cell viability below 25 μM.										
<b>In Vivo</b>	<p>ACHe-IN-59 (compounds 3b) (25 μM, 3 days) can alleviate the behavioral effects of AlCl<sub>3</sub>-induced zebrafish larval movement retardation<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>zebrafish juveniles with 5 mg/L AlCl<sub>3</sub> model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5/10/25/50/100 μg/mL,</td> </tr> <tr> <td>Administration:</td> <td>Soak drug administration</td> </tr> </table>			Animal Model:	zebrafish juveniles with 5 mg/L AlCl <sub>3</sub> model <sup>[1]</sup>	Dosage:	5/10/25/50/100 μg/mL,	Administration:	Soak drug administration		
Animal Model:	zebrafish juveniles with 5 mg/L AlCl <sub>3</sub> model <sup>[1]</sup>										
Dosage:	5/10/25/50/100 μg/mL,										
Administration:	Soak drug administration										

---

Result:

Had certain therapeutic effect on  $AlCl_3$ -induced zebrafish behavior inhibition, which was concentration-dependent. With the increase of compound concentration, the total distance of zebrafish larvae increased gradually.

---

## REFERENCES

---

[1]. Zhai J, et al. Design, synthesis, and evaluation of dual-target inhibitors for the treatment of Alzheimer's disease. Arch Pharm (Weinheim). 2024 Feb 8:e2300693.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA